Radius Health Inc (RDUS) Given Consensus Recommendation of “Hold” by Brokerages
Radius Health Inc (NASDAQ:RDUS) has earned an average rating of “Hold” from the twelve analysts that are covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $48.63.
RDUS has been the topic of a number of research analyst reports. BidaskClub lowered Radius Health from a “sell” rating to a “strong sell” rating in a research note on Wednesday, June 6th. Cantor Fitzgerald set a $58.00 target price on Radius Health and gave the stock a “buy” rating in a research note on Monday, June 11th. JPMorgan Chase & Co. upped their target price on Radius Health from $56.00 to $60.00 and gave the stock an “overweight” rating in a research note on Monday, June 11th. Bank of America decreased their target price on Radius Health from $51.00 to $47.00 and set a “buy” rating on the stock in a research note on Wednesday, July 25th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $25.00 target price on shares of Radius Health in a research note on Tuesday, August 7th.
Shares of RDUS opened at $17.45 on Thursday. The stock has a market cap of $787.20 million, a P/E ratio of -3.01 and a beta of 0.93. The company has a debt-to-equity ratio of 1.26, a quick ratio of 5.26 and a current ratio of 5.39. Radius Health has a 52-week low of $16.71 and a 52-week high of $41.16.
In other news, major shareholder Growth N. V. Biotech acquired 60,000 shares of Radius Health stock in a transaction dated Monday, August 20th. The shares were purchased at an average cost of $19.65 per share, for a total transaction of $1,179,000.00. Following the transaction, the insider now owns 6,590,276 shares of the company’s stock, valued at $129,498,923.40. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Growth N. V. Biotech acquired 50,000 shares of Radius Health stock in a transaction dated Friday, July 27th. The shares were purchased at an average price of $24.81 per share, for a total transaction of $1,240,500.00. Following the completion of the transaction, the insider now directly owns 6,300,913 shares in the company, valued at approximately $156,325,651.53. The disclosure for this purchase can be found here. Insiders acquired a total of 389,363 shares of company stock worth $8,675,131 over the last 90 days. Corporate insiders own 3.42% of the company’s stock.
Several institutional investors have recently made changes to their positions in RDUS. NumerixS Investment Technologies Inc bought a new position in shares of Radius Health during the 2nd quarter valued at about $162,000. Xact Kapitalforvaltning AB bought a new position in shares of Radius Health during the 1st quarter valued at about $213,000. Aperio Group LLC bought a new position in shares of Radius Health during the 1st quarter valued at about $231,000. Cubist Systematic Strategies LLC increased its position in shares of Radius Health by 9,303.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 9,403 shares of the biopharmaceutical company’s stock valued at $277,000 after purchasing an additional 9,303 shares during the last quarter. Finally, Raymond James & Associates increased its position in shares of Radius Health by 15.0% during the 2nd quarter. Raymond James & Associates now owns 18,766 shares of the biopharmaceutical company’s stock valued at $553,000 after purchasing an additional 2,449 shares during the last quarter.
About Radius Health
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.
Featured Article: Average Daily Trade Volume – ADTV
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.